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Background: Allergic contact dermatitis (ACD) develops upon exposure to certain chemical compounds termed
skin sensitizers. To reduce the occurrence of skin sensitizers, chemicals are regularly screened for their capacity to
induce sensitization. The recently developed Genomic Allergen Rapid Detection (GARD) assay is an in vitro
alternative to animal testing for identification of skin sensitizers, classifying chemicals by evaluating transcriptional
levels of a genomic biomarker signature. During assay development and biomarker identification, genome-wide
expression analysis was applied using microarrays covering approximately 30,000 transcripts. However, the
microarray platform suffers from drawbacks in terms of low sample throughput, high cost per sample and time
consuming protocols and is a limiting factor for adaption of GARD into a routine assay for screening of potential
sensitizers. With the purpose to simplify assay procedures, improve technical parameters and increase sample
throughput, we assessed the performance of three high throughput gene expression platforms - nCounter®,
BioMark HD™ and OpenArray® - and correlated their performance metrics against our previously generated
microarray data. We measured the levels of 30 transcripts from the GARD biomarker signature across 48 samples.
Detection sensitivity, reproducibility, correlations and overall structure of gene expression measurements were
compared across platforms.
Results: Gene expression data from all of the evaluated platforms could be used to classify most of the sensitizers
from non-sensitizers in the GARD assay. Results also showed high data quality and acceptable reproducibility for
all platforms but only medium to poor correlations of expression measurements across platforms. In addition,
evaluated platforms were superior to the microarray platform in terms of cost efficiency, simplicity of protocols and
sample throughput.
Conclusions: We evaluated the performance of three non-array based platforms using a limited set of transcripts
from the GARD biomarker signature. We demonstrated that it was possible to achieve acceptable discriminatory
power in terms of separation between sensitizers and non-sensitizers in the GARD assay while reducing assay costs,
simplify assay procedures and increase sample throughput by using an alternative platform, providing a first step
towards the goal to prepare GARD for formal validation and adaption of the assay for industrial screening of
potential sensitizers.
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Allergic contact dermatitis (ACD) is characterized by
redness of the skin, accompanied by periodic and recur-
rent episodes of itching [1]. The disease is a type IV de-
layed type hypersensitivity reaction initiated and mediated
by cytotoxic CD8+ T cells and CD4+ Th1 cells [2] and de-
velops upon repeated or prolonged exposure to contact al-
lergens [3]. With a prevalence of 15-20% [4,5], ACD has
rapidly become a major occupational and environmental
health problem [6,7]. ACD is a chronic condition and the
recommendation to affected individuals is complete avoid-
ance of inducing contact allergen [3].
Contact allergens capable of inducing ACD are termed
skin sensitizers. An important group of skin sensitizers
are chemical compounds present in common household
products such as cosmetics and personal care products.
To limit and control the use of sensitizers in such prod-
ucts, chemicals are regularly screened for their capacity to
induce sensitization. Historically, such assays have relied
exclusively on animal experimentation, with the murine
local lymph node assay (LLNA) [8] being the preferred
method. However, as of March 2013, an EU legislation [9]
imposed a ban on the use of animals for safety assessment
of cosmetic products, regardless of the availability of non-
animal test as an alternative to animal testing. Thus, the
demand for alternative in vitro methods for prediction of
chemical sensitization is urgent.
Recently, we developed the Genomic Allergen Rapid
Detection (GARD) assay, a novel alternative to animal
testing for identification and risk assessment of human
skin sensitizing chemicals using a predictive genomic
biomarker signature termed the GARD prediction signa-
ture (GPS) [10]. The GPS was established using a panel
of reference chemicals comprising 18 well known sensi-
tizers and 20 non-sensitizers. By stimulating the myeloid
cell line MUTZ-3 with the panel of reference chemicals,
we were able to identify the 200 most potent discrimin-
atory transcripts between non-sensitizers and sensitizers.
The information given by differentially expressed tran-
scripts in the GPS was used to train a support vector ma-
chine model (SVM) [11]. Subsequently, the SVM model is
used for classification of unknown chemical compounds
as either sensitizers or non-sensitizers.
The technical format currently used for transcrip-
tional analysis in the GARD assay is Affymetrix® whole-
transcriptome microarrays. The array platform has been
valuable during assay development to identify differen-
tially regulated genes in the GPS from the entire transcrip-
tome, yet it suffers from drawbacks in terms of low
sample throughput, high cost per sample and time con-
suming protocols. Furthermore, the microarray platform
has known limitations in terms of sensitivity, reproducibil-
ity and dynamic range [12-15]. For an in vitro method
to be used for regulatory purposes and eventually forindustrial screening of sensitizers, it needs to be validated
according to internationally recognized procedures [16].
With the purpose to prepare GARD for formal validation
under the supervision of The European Union Reference
Laboratory for alternatives to animal testing (EURL ECVAM),
and in order to simplify assay procedures, improve technical
parameters and increase sample throughput, the GARD
assay would benefit from a technical platform transfer.
The number of available technologies for high throughput
quantitative transcriptome analysis is steadily increasing,
but only a handful of comparisons between gene expres-
sions measurements on various platforms exist. Thus,
there is a need to evaluate and compare results obtained
from the various technologies to assess reliability and bio-
logical significance of measurements. We performed a sys-
tematic head to head comparison to assess the performance
of three of the most prominent high throughput gene ex-
pression platforms, including the nCounter® analysis sys-
tem (NanoString® technologies) [17], BioMark HD™
system (Fluidigm® corporation) [18] and the OpenArray®
system (Life Technologies™) [19]. The nCounter® analysis
system is a novel hybridization based technology enabling
gene expression measurements to be performed directly
from cell lysate. The technology use transcript specific
color coded molecular probe pairs to capture and
count individual transcripts and has several advantages
in comparison to microarray platform including easy pro-
tocols, less hands-on time and higher sample throughput
[17]. BioMark HD™ and OpenArray® are RT-qPCR based
technologies which is considered as the gold standard for
quantitative transcription analysis due to its high sensitiv-
ity, high reproducibility and large dynamic range [19-21].
RT-qPCR is however a low throughput technology in its
conventional format. Utilizing slightly different strategies,
both BioMark HD™ and the OpenArray® system provides
technologies that aims to conserve the intrinsic analytical
benefits of the conventional RT-qPCR while enabling gene
expression measurement in a high throughput format
[22]. Both systems use streamlined protocols that enable
progression from cDNA into results in less than three
hours for the OpenArray® system and less than seven
hours for the BioMark HD™ system. In this report, we
present a per application relevant comparison and evalu-
ation of the nCounter®, BioMark HD™ and the OpenArray®
platforms in the context of the GARD assay. This report is
not intended to serve as a general recommendation of a
particular platform, but rather to investigate the trade-offs
in terms of price, throughput, protocols, analytical per-
formance and applicability of a selection of high through-
put platforms for the GARD assay. Primary focuses were
to compare non-technical parameters such as sample
throughput, price per sample and simplicity of protocols
between the platforms as well as to evaluate the more
technical parameters in terms of precision and data
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consistency, and to determine if transcriptional analysis
performed on the evaluated platforms could be applied
to the GARD model to classify sensitizers from non-
sensitizers. In conclusion, we found that it was possible to
achieve acceptable detection sensitivity, reproducibility
and discriminatory power of the GARD assay while at the
same time simplify assay procedures and reduce assay cost
when using any of the suggested high-throughput plat-
forms evaluated in this study.
Results
Biological model for evaluation of high throughput
platforms and phenotypic analysis of unstimulated
MUTZ-3 cells
The GARD assay was chosen as a biological model to
achieve a per application relevant assessment of the per-
formance of selected high throughput platforms. The cell
line used in the GARD assay is the dendritic cell (DC)-like
human myeloid leukemia-derived cell line MUTZ-3 [23].
Analogous to primary DCs, MUTZ-3 cells express CD1a,
HLA-DR, CD54, CD80 and CD86. The MUTZ-3 popula-
tion also consists of subpopulations of CD14+, CD34+
and double negative cells as previously described [24].
Phenotypic analysis of cells was performed prior to each
round of stimulation to ensure that MUTZ-3 cells were in
an immature stage. Cell surface expression levels of the
markers CD54, CD86, CD80, HLA-DR, CD14, CD34 and
CD1a were verified using flow cytometry prior to stimula-
tions. Results are illustrated in Table 1 and correlated with
previously published examples of phenotypic profiles for
the MUTZ-3 cells [10].
Inducible up-regulation of CD86 cell surface marker in
response to stimulation of MUTZ-3 with skin sensitizers
To enable a comprehensive evaluation between platforms,
a panel of 16 chemical compounds including eight sensi-
tizers and eight non-sensitizers initially being used to define
the GARD prediction signature (GPS) were prepared for
stimulation of MUTZ-3 cells (Table 2). Each stimulationTable 1 Phenotype of MUTZ-3 cells








Expression levels of the cell surface markers CD54,CD80,CD86,HLA-DR,CD1a,
CD14 and CD34 were determined using flow cytometry to ensure proliferating
cells were not differentiated. Results illustrates average percentage of positive
cells together with standard deviation (n = 3).was performed in biological triplicates, generating a data-
set comprising 48 chemical stimulations. The GARD assay
uses the inducible cell surface expression of CD86 after
chemical stimulation as a general measure of the maturity
state of the cells and as a quality control to ensure bio-
availability of chemical stimulations. Cell surface expres-
sion of CD86 was confirmed after 24 h of stimulation with
chemicals using flow cytometry (Figure 1). CD86 was
significantly up-regulated on cells stimulated with the
sensitizers 2-hydroxyethyl acrylate, 2-aminophenol, 2-
nitro-1,4-phenylendiamine and p-phenylendiamine in com-
parison to vehicle controls. None of the non-sensitizers
induced a significant up-regulation of CD86. The outcome
of the experiment correlated with previously published
data [10].
Transcriptional profiling of MUTZ-3 using high throughput
gene expression platforms
Selection of transcripts for this study was performed in
two consecutive steps. In a first step, transcripts were se-
lected in order to obtain a representative expression profile
from the GPS to allow for a decisive evaluation of technical
parameters such as intra platform reproducibility and limit
of detection. In this step, transcripts were selected to cover
the whole dynamic range of gene expression present in the
original GPS (including low, medium and highly expressed
transcripts) as well as to include heavily regulated tran-
scripts, weakly regulated transcripts and to include both
up- and down regulated transcripts when comparing ex-
pression profiles of chemically stimulated cells to non-
stimulated cells. For the transcripts selected in the first
step, a second round of selection was performed to include
only the most potent predictor genes to allow for assess-
ment of the biological relevance of gene expression data in
terms of the GARD assay. Selection of the most potent
predictor genes were based on validation call frequencies
as described in [10]. The abundance of each transcript in-
cluded in this study (Table 3) was determined on all plat-
forms using samples from the same cellular stimulation.
Data were analyzed to evaluate intra-platform reproduci-
bility, inter-platform reliability and relevance of data pro-
duced on each platform for construction of a predictive
model for skin sensitization in the GARD assay. A sche-
matic view of the experimental workflow from chemical
stimulation to mRNA quantification using the various
platforms is illustrated in Figure 2. The data from the high
throughput platforms were compared to Affymetrix®
microarray data from a previous study [10]. A comparison
of non-technical parameters of evaluated platforms is il-
lustrated in Table 4.
Preprocessing of data
Gene expression data obtained on evaluated platforms
were normalized prior to any analysis as described in
Table 2 List of chemical compounds used during evaluation of platforms
Compound Abbrev. Potency according to LLNA Vehicle GARD input concentration (μM)
Sensitizers
2-Aminophenol 2-AP Strong DMSO 100
2-nitro-1,4-phenylenediamine NPDA Strong DMSO 300
p-Phenylenediamine PPD Strong DMSO 75
Ethylenediamine EDA Moderate Water 500
2-hydroxyethyl acrylate 2-HA Moderate Water 100
Eugenol EUG Weak DMSO 300
Geraniol GER Weak DMSO 500
Penicillin G PEN G Weak Water 500
Non-sensitizers
1-Butanol BUT DMSO 500
Dimethyl formamide DF Water 500
Ethyl vanillin EV DMSO 500
Metyl salicylate MS DMSO 500
Propylene glycol PG Water 500
Salicylic acid SA DMSO 500
Vehicle controls
Water dH2O - -
Dimethyl sulfoxide DMSO - -
List of chemical compounds used for evaluation of platforms. List includes information on sensitizing potency, vehicle, GARD input concentration and
abbreviation for each chemical.
Figure 1 Cell surface expression of CD86 in MUTZ-3 cells after stimulation with sensitizing and non-sensitizing chemicals. Levels of
expression of the cell surface marker CD86 were determined using flow cytometry after stimulation with various chemicals for 24 h. Figure
illustrates percentage of CD86 positive cells for each chemical (n = 3). Gating were performed to exclude dead cells/debris and quadrants were
established by comparing with isotype controls. Statistics were performed using Student’s t-test (*p < 0.05).
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Table 3 List of transcripts used during evaluation of platforms
Gene symbol Entrez gene ID DELTAGene™ assay ID NanoString® probe ID Life technologies™ assay ID
ADAM20 8748 GEP00055625 NM_003814.4:1420 Hs01083178_s1
CD33 945 GEP00055628 NM_001177608.1:730 Hs00233544_m1
CD86 942 GEP00055621 NM_175862.3:1265 Hs01567026_m1
CD93 22918 GEA00016079 NM_012072.3:4270 Hs00362607_m1
DHCR24 1718 GEA00025118 NM_014762.2:975 Hs00207388_m1
DHX33 56919 GEP00055629 NM_001199699.1:2873 Hs01063767_m1
FAS 355 GEP00055622 NM_152876.1:1740 Hs00907759_m1
FASN 2194 GEA00032375 NM_004104.4:5387 Hs00188012_m1
FDXR 2232 GEA00028039 NM_004110.3:1123 Hs01031618_g1
GDAP2 54834 GEA00028183 NM_001135589.1:640 Hs00214424_m1
GDF11 10220 GEA00006411 NM_005811.3:3590 Hs00195156_m1
GNL3L 54552 GEA00029786 NM_001184819.1:1935 Hs00535521_m1
HIST1H3J 8356 GEA00014232 NM_003535.2:364 Hs00361917_s1
HMGCS1 3157 GEA00026981 NM_002130.4:420 Hs00940429_m1
HNRNPL 3191 GEA00029122 NM_001533.2:757 Hs00704853_s1
LY96 23643 GEP00055624 NM_015364.2:360 Hs01026734_m1
MAPK13 5603 GEP00055633 NM_002754.3:1050 Hs00559623_m1
MTR 4548 GEA00030234 NM_000254.2:6816 Hs00299285_s1
NQO1 1718 GEA00013124 NM_000903.2:790 Hs02512143_s1
OR5B21 219968 GEA00014658 NM_001005218.1:292 Hs02339238_s1
PFAS 5198 GEA00032277 NM_012393.2:4655 Hs00389822_m1
PHLDA3 23612 GEA00015249 NM_012396.3:532 Hs01926548_s1
RFC2 5982 GEP00055631 NM_181471.1:835 Hs00945948_m1
SFPQ 6421 GEP00055626 NM_005066.2:1995 Hs00192574_m1
SLC37A4 2542 GEP00055634 NM_001164277.1:1248 Hs00184616_m1
SQLE 6713 GEP00055620 NM_003129.3:250 Hs01123768_m1
TLR6 10333 GEA00012581 NM_006068.2:2530 Hs00271977_s1
TMEM97 27346 GEP00055627 NM_014573.2:2055 Hs00299877_m1
TXNRD1 7296 GEA00013820 NM_001093771.1:1009 Hs00917067_m1
ABCB4 5244 GEP00055630 NM_018849.2:2125 Hs00240956_m1
GAPDH 2597 GEP00055153 NM_002046.3:972 Hs03929097_g1
HPRT1 3251 GEP00055483 NM_000194.1:240 Hs99999909_m1
A set of 30 transcripts from the GPS was analyzed on all three platforms. Transcripts are listed by gene symbol, Entrez Gene ID, DELTAGene™ assay ID,
NanoString® probe ID and Life Technologies™ Assay ID. In addition to transcripts from the GPS, three reference transcripts, ABCB4, GAPDH and HPRT1 were
analyzed on the evaluated platforms and used for normalization of data.
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RNA preparation, one of the replicates from the follow-
ing chemical stimulations had to be removed from analysis
on all platforms: p-phenylendiamine, geraniol, eugenol and
1-butanol. In addition, one of the replicates from the fol-
lowing chemical stimulations had to be removed from ana-
lysis on nCounter® platform due to platform specific issues:
2-aminophenol and water. Total dataset analyzed on
nCounter® consisted of 42 samples. In addition to the sam-
ples removed due to issues during RNA preparation, one
of the replicates from the following chemical stimulationshad to be removed from analysis on BioMark HD™ and
OpenArray® platforms due to insufficient amounts of
cDNA: propylene glycol, methyl salicylate, geraniol and di-
methyl sulfoxide. Total dataset analyzed on BioMark HD™
and OpenArray® consisted of 40 samples. All stimulations
except geraniol was present in at least biological duplicates.
For chemical stimulations consisting of two replicates, av-
eraged values were calculated from duplicate reactions in-
stead of on triplicate as applied to remaining stimulations.
The total number of sample shared between all platforms
comprised 38 samples.
Figure 2 Experimental workflow for evaluation of high throughput platforms. Schematic view of the experimental design illustrating the
procedure from chemical stimulation to mRNA quantification on the various platforms.
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To determine how evaluated platforms compared in sen-
sitivity to each other, we estimated the total number of
transcripts detected on each platform. Using the set of
38 chemical stimulations shared between all platforms
and measuring the expression levels of all 33 transcripts
in each stimulation, a total of 1254 transcripts were
assayed on each platform. Transcripts were defined as ei-
ther detected or undetected in a certain chemical stimula-
tion based on platform specific criteria as described in
Methods. The overall number of detected transcripts in allTable 4 Comparison of platforms
Platform Affymetrix® nCounter®
Technology Microarray Hybridization
Input material cDNA Total RNA
Sample consumption 300 ng total RNA/sample 200 ng total RNA/sam
Time for analysis ~4 days from RNA
to results
22 h from RNA to results
a hands on time of 15 m
Protocols Difficult Easy
Pricea $$$$ $$$
Comparison are based on the 48 samples analyzed in the present study. a Platform
The number of $ denotes the relation in costs between the platforms, with the highsamples was higher on the BioMark HD™ platform (1246/
1254) in comparison to both the OpenArray® platform
(1210/1254) and the nCounter® platform (1128/1254). In
order to generate a uniform set of transcripts for com-
parative analysis between the platforms, we chose to in-
clude only those transcripts detected in at least two of the
three replicate reactions for all stimulations and on all
of the evaluated platforms during downstream ana-
lysis. Identities and number of detected transcripts for
all stimulations and on each platform are summarized
in Table 5. While all transcripts were detected in atBioMark HD™ OpenArray®
RT-qPCR RT-qPCR
Pre-Amp cDNA cDNA
ple 125 ng cDNA/sample 120 ng cDNA/sample
with
inutes.
7 h from cDNA to results with
a hands on time of ~ 4 h
3 h from cDNA to results with a
hands on time of 20 minutes.
Medium Easy
$ $$
s were graded based on total cost to analyze the complete set of 48 samples.
est number assigned to the most expensive platform.
Table 5 Comparison of the number of detected genes in
the 38 samples shared between all platforms
Gene symbol nCounter® BioMark HD™ OpenArray®
ABCB4 1 (3%) 31 (82%) 18 (47%)
FDXR D 37 (97%) 36 (95%)
OR5B21 0 (0%) D 37 (97%)
ADAM20 11 (29%) D 35 (92%)
HIST1H3J 36 (95%) D 36 (95%)
GDF11 30 (79%) D D
LY96 D D 36 (95%)
TLR6 36 (95%) D D
CD86 33 (87%) D 36 (95%)
FASN D D 37 (97%)
PFAS D D 36 (95%)
MAPK13 37 (97%) D D
GDAP2 D D 36 (95%)
TMEM97 35 (92%) D D
DHX33 35 (92%) D D
RFC2 D D 37 (97%)
ACLY D D 35 (92%)
TXNRD1 D D 37 (97%)
HPRT1 D D 37 (97%)
GAPDH D D 37 (97%)
The set of 33 transcripts were measured in the 38 chemical stimulations
shared between all platforms. The table illustrates the number of detected
calls for a specific transcript across the 38 samples with percentage in
parentheses. Table lists only transcripts declared as undetected in any of the
stimulations on either nCounter®, BioMark HD™ or OpenArray®. D denotes that
transcript is present in all samples.
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on BioMark HD™, one transcript (ABCB4) on the
OpenArray® platform, and three transcripts (ABCB4,
ORB5B21 and ADAM20) on the nCounter® platform,
did not fulfill the stringent requirements for use in
downstream analysis. Subsequently, ABCB4, ORB5B21
and ADAM20 were removed from the set of tran-
scripts. Two of the removed transcripts, ORB5B21
and ADAM20 originated from the GPS while the
transcript ABCB4 was originally considered to be
used as a reference gene. All of the removed tran-
scripts were confirmed as low expressed transcripts in
the MUTZ-3 cell line based on microarray data (data
not shown). The total gene set used for further ana-
lysis thus consisted of a total of 28 transcripts from
the GPS.
Intra-platform reproducibility and data consistency
We chose to evaluate precision and to measure data
consistency within each platform by calculating coeffi-
cient of variation (CV%) between biological replicatemeasurements. Calculations of CV were performed on
intra-platform replicates for each chemical stimulation
using quantitative gene expression signals from the subset
of 28 transcripts shared between the evaluated platforms.
The distribution of replicate CV values across all tran-
scripts are summarized in a series of box and whiskers
plots visualized in Figure 3. All platforms demonstrated
good reproducibility of gene expression data. The replicate
CV median values for Affymetrix® were the lowest
amongst the platforms, ranging from 1-3% for all chemical
stimulations. The replicate CV median values for the
majority of the chemical stimulations measured on
nCounter®, BioMark HD™ and OpenArray® platforms
were in the range of 5-15%, although the distribution
of replicate CV varied slightly between various chemical
stimulations measured on the same platform. Examples
include larger dispersion of replicate CV values for the
stimulations ethyl vanillin, 1-butanol, salicylic acid, methyl
salicylate, dimethyl formamide, dimethyl sulfoxide and
water in comparison to 2-aminophenol, 2-nitro-1,4-phe-
nylendiamine, p-phenylendiamine and ethylendiamine.
However, the pattern of dispersion of the CV values for
the different stimulations seems to be comparable across
the evaluated platforms.
Inter-platform consistency
We further evaluated reliability of gene expression data
measured on the nCounter®, BioMark HD™ and OpenArray®
platforms by comparing their abilities to measure tran-
scripts in the GARD signature to each other and to
Affymetrix® microarrays. Absolute signals of gene ex-
pression values generated on the different platforms could
not be compared directly since the different platforms uti-
lized different chemistry, quantitation, and normalization
methods. Therefore, we evaluated the correlation between
data in fold change matrices. Cross-platform comparisons
were performed by evaluating concordances of log2 fold
changes by pair wise regression analysis of fold differences
for chemical stimulations in comparison to vehicle con-
trols. Biological replicate measurements for the 38 sam-
ples shared between all platforms were used to calculate
the average log2 fold changes across the 28 transcripts
present in each stimulation. Dimethyl sulfoxide and water
were used as reference samples. The chemical stimulation
geraniol was removed from the analysis as no replicate
samples were available. This left a dataset consisting of
364 matched measurement pairs (averaged values from 13
stimulations). The matched measurement pairs from each
platform were pair-wise plotted against each other and
subjected to bivariate analysis. Pearson correlation coeffi-
cients and linear fits to the log2 ratios were calculated
for each pair-wise platform comparison (Figure 4). Strong
correlation was observed between log2 fold change mea-
surements on nCounter® and BioMark HD™ platforms
Figure 3 Distribution of replicate coefficient of variation (CV). As a measure of intra-platform precision and data consistency, the replicate
CV of 28 transcripts present in all stimulations were determined from triplicate stimulations and illustrated in a series of box and whiskers
plots. The interquartile range (25th and 75th percentile), median (Gap) and the 10th and 90th percentile values as well as outliers are
indicated in each plot.
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either of BioMark HD™ (Figure 4B, R = 0.44) or nCounter®
(Figure 4C, R = 0.50) to Affymetrix®. Low correlations
were also observed between log2 fold change measure-
ments of either of BioMark HD™ (Figure 4D, R = 0.53),
nCounter® (Figure 4E, R = 0.50) and Affymetrix® (Figure 4F,
R = 0.14) with the OpenArray® data. Level of compression
or expansion of gene expression data measured on the
different platforms were evaluated by comparing the
slope of the best fitted line of a least square linear re-
gression of the log2 fold changes between pairs of plat-
forms to the ideal slope of 1. Only a minor compression
was observed between nCounter® and BioMark HD™
(slope: 0.83). Compression effects were observed for both
nCounter® (slope = 0.33) and BioMark HD™ (slope 0.35) in
relation to OpenArray®. Affymetrix® data compressed log2
fold change measurements relative to the other platforms
(slope 0.12, 0.18, 0.040 for BioMark HD, nCounter® and
OpenArray® respectively).Comparison of transcriptional profiles from different
platforms as predictive models for skin sensitization
We evaluated overall structure and relevance of gene ex-
pression data measured on evaluated high-throughput
platforms on a per application basis in order to deter-
mine if platforms could be used to distinguish sensitizers
from non-sensitizers in the GARD assay. Principal compo-
nent analysis (PCA) was used to visualize gene expression
data from the various platforms. PCA plots were con-
structed in the software Qlucore Omics Explorer v.2.1
using the subset of 28 transcripts shared between evalu-
ated platforms as variable input. Construction of PCA
plots based on the 40 samples in the BioMark HD™ and
OpenArray® sample datasets revealed significant outliers
that had to be removed, otherwise they would have pre-
vented visualization and classification of separate groups
(data not shown). From the BioMark HD™ data set,
one of the replicate of dimethyl formamide had to be
removed, leaving a dataset comprising 39 samples. From
Figure 4 Fold change correlations between gene expression data quantified by the various platforms. Cross-platform comparisons were
performed by evaluating the concordance of log2 fold changes by pair wise regression analysis of fold differences for chemical stimulations in
comparison to vehicle controls. The average log2 fold changes for 28 transcripts present in all stimulations and detected on all three platforms
were subjected to bivariate analysis. Subplots (A-F) illustrates the correlation between the following platforms: A) nCounter® and BioMark HD™,
B) Affymetrix® and BioMark HD™, C) Affymetrix® and nCounter®, D) BioMark HD™ and OpenArray®, E) nCounter® and OpenArray®, F) Affymetrix®
and OpenArray®. The solid line in each plot illustrates the linear regression fit while the dashed line represents the 1.0 slope of complete
concordance. Pearson correlation coefficients (R) and equation for the linear fit (y) are indicated for each subplot. P-values for hypothesis of no
correlation were calculated using Fisher’s transformation (P).
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amide, 1-butanol, methyl salicylate and water had to be re-
moved, leaving a dataset comprising 36 samples. All 42
samples measured on nCounter® were employed for con-
struction of the nCounter® PCA plot. For comparative rea-
sons, a PCA plot was constructed based on Affymetrix®
gene expression measurements of the 48 samples origin-
ally selected for this evaluation using the subset of 28 tran-
scripts shared between evaluated platforms as variable
input. To determine if gene expression measurements
from evaluated platforms could be used to distinguish sen-
sitizers from non-sensitizers, each sample in the PCA
plots was colored according to sensitizing potency as de-
fined by the LLNA assay (Figure 5). Neither of the evalu-
ated platforms were able to achieve a complete separation
of sensitizers and non-sensitizers. The PCA plot con-
structed from nCounter® data showed highest level of
similarity to the Affymetrix® PCA plot. For both theseplatforms, discrimination between sensitizers and non-
sensitizers were seen along the first principal component.
While all strong sensitizers clustered together, separated
from the non-sensitizers, a few of the moderate and all
the weak sensitizers clustered close to the non-sensitizers
for the Affymetrix® platform, and together with the non-
sensitizers for the nCounter® platform. The separation
profiles for both the BioMark HD™ and the OpenArray®
platforms demonstrated a clear discrimination between
strong sensitizers and non-sensitizers while a few moder-
ate sensitizers and most weak sensitizers clustered to-
gether with non-sensitizers. However, in contrast to the
nCounter® and the Affymetrix® data, discrimination be-
tween sensitizers and non-sensitizers was observed along
the second principal component. To further investigate
the quality and similarity of gene expression data pro-
duced on the various platforms for the different chemical
stimulations, each sample in the PCA plot was instead
Figure 5 Principal component analysis (PCA) of gene expression data after 24 h of chemical stimulation. To investigate overall similarities
of gene expression data and to outline relevance of data from evaluated platforms for the GARD assay, gene expression data from 28 transcripts
shared between all platforms were used for construction of PCA plots in the software Qlucore. Samples were colored according to sensitizing
potency as defined by the LLNA assay. Subplots (A-D) illustrates PCA plots constructed from gene expression data obtained on the various
platforms. A) Affymetrix®, 48 stimulations (weak (n = 9), moderate (n = 6), strong (n = 9), non-sensitizer (n = 24)). B) nCounter®, 42 stimulations
(weak (n = 7), moderate (n = 6), strong (n = 7), non-sensitizer (n = 22)). C) BioMark HD, 39 stimulations (weak (n = 6), moderate (n = 6), strong
(n = 8), non-sensitizer (n = 19). D) OpenArray®, 36 stimulations (weak (n = 6), moderate (n = 6), strong (n = 8), non-sensitizer (n = 16).
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important observations were made: Firstly, the moderate
sensitizer that consistently clustered together with the
non-sensitizers for all platforms could be identified as be-
ing the same chemical, ethylendiamine. Secondly, replicate
stimulations grouped together in all PCA plots, indicating
high quality data from all platforms.
Discussion
The GARD assay was recently developed as an in vitro alter-
native to animal testing for identification and classification
of skin sensitizers. The assay classifies chemicals as either
skin sensitizers or non-sensitizers with high accuracy, sensi-
tivity and specificity, using a genomic biomarker signature
in the myeloid cell line MUTZ-3. The MUTZ-3 cell line is
ideal for assay development as they resemble dendritic cells
(DCs) which are important modulators of immune reactionsin response to foreign substances [24]. The use of a cell line
in the GARD assay ensures a constant supply of cells and
enables a large number of cells to be grown via standardized
protocols in short time, allowing for a capability to scale up
the format of the assay. We believe that the testing strategy
behind the GARD assay has potential to replace animal
experimentation for classification of chemicals, but that the
technical platform currently used for transcriptome analysis,
the microarray platform, is a limiting factor for adaption of
GARD into a routine assay for analysis and screening of
potential sensitizers. To improve GARD and place the assay
in a better position for formal validation following an estab-
lished assessment procedure with the ultimate aims to sim-
plify assay procedures, improve technical parameters and
increase sample throughput, we assessed the performance of
three high throughput platforms for gene expression mea-
surements and correlated their performance metrics against
Figure 6 Principal component analysis (PCA) of gene expression data after 24 h of chemical stimulation. To investigate consistency of
gene expression data from evaluated platforms, samples from Figure 5 were instead colored according to chemical stimulation. Subplots (A-D)
illustrates PCA plots constructed from gene expression data obtained on the various platforms. A) Affymetrix®, 48 stimulations. B) nCounter®,
42 stimulations. C) BioMark HD, 39 stimulations. D) OpenArray®, 36 stimulations.
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sured the levels of 30 representative genes from the GPS
across 48 samples on all platforms. Samples comprised 16
chemical stimulations in biological triplicate reactions and
included both sensitizers and non-sensitizers. To achieve a
comprehensive evaluation, we applied an experimental de-
sign allowing us to perform measurements on all platforms
from the same chemical stimulation and a single RNA prep-
aration. Thus, only platform-specific protocols downstream
from RNA isolation discriminated between measurements
on the different platforms.
The key findings from the current study are threefold.
Firstly, good intra-platform reproducibility of gene expres-
sion data for all platforms was observed. Secondly, all
evaluated platforms displayed modest to low correlation of
gene expression measurements compared to Affymetrix®
microarray data. Thirdly, all platforms were able to discrim-
inate most of the extreme and moderate skin sensitizers
from non-sensitizers when gene expression data obtained
from the various platforms were subjected to PCA analysis.High intra-platform reproducibility of gene expression
measurements was considered a key criterion during the
evaluation of platforms. High reproducibility might reduce
number of replicates needed for measurements, affecting
experimental design, sample throughput and eventually also
costs. Considering that evaluated platforms not only use
different technology for gene expression measurements but
also different protocols for preparation of samples prior to
final quantification, we chose to calculate precision based
on biological replicate measurements where replicates for
each stimulation was prepared individually for analysis
according to protocols for a certain platform. Thus, the
estimated precision included both technical variations
during final measurements as well as variations possibly in-
troduced during sample preparation prior to quantification.
The present study demonstrates high intra-platform preci-
sion for all platforms. The majority of replicate CV median
measurements for nCounter®, BioMark HD™ and Open-
Array® were in the range between 5-15% which was slightly
higher than the CV values observed on the Affymetrix®
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Affymetrix® platform, the distribution of replicate CV values
varies between stimulations on evaluated platforms. The
distribution of replicate CV values for a certain stimulation
is however comparable across the evaluated platforms.
Considering that a single stimulation was prepared for
analysis on nCounter®, BioMark HD™ and OpenArray®,
while Affymetrix® data was based on previously generated
data it is likely that the higher CV values observed for the
evaluated platforms in comparison to Affymetrix® originate
from sample preparation and not from the quantification
itself. In addition, evaluated genes were chosen by a data-
driven approach, using the Affymetrix® data as an explora-
tory data set. Thus, the very low CV values observed for
Affymetrix® data might be explained by a selection bias.
The multiple steps included in sample preparation (RNA to
cDNA preparation, data acquisition, normalization of data)
are all possible steps for introduction of variations. The
nCounter® system has the simplest protocol since measure-
ments can be performed directly on RNA samples and in a
single reaction. The OpenArray® system requires reverse
transcription, but most steps in the analysis is fully
automated using a mechanic liquid handler. Finally, the
BioMark HD™ system requires both reverse transcription,
pre-amplification and several steps of technical pipetting.
However, these differences did not seem to affect the repro-
ducibility of the measurement to any large extent as
indicated by the similarity in CV values across platforms.
In contrast to reproducibility measurements, we also
reported differences in the number of transcripts that could
be detected on each of the evaluated platforms. Reasons for
not detecting a transcript can be explained by a bad probe
for the specific gene or insufficient sample target concen-
tration. Since high frequencies of undetected genes corre-
lated well with low levels of expression, we suggest that the
major contribution in this study was due to transcript levels
under the limit of detection for the specific platform.
Results indicate superior sensitivity of the BioMark HD™
platform in comparison to both nCounter® and Open-
Array®. The increased detection sensitivity may be linked to
the additional cDNA pre-amplification step implemented
prior to RT-qPCR on BioMark HD™. In contrast, the
nCounter® platform does not involve any target amplifica-
tion and the OpenArray® technology involves amplification
only during the RT-qPCR reaction when using standard
protocols. An unexpected observation was also that the
performance of the reference transcripts were different
between the platforms (data not shown). While both
GAPDH and HPRT1 performed equally well on nCounter®,
only GAPDH performed satisfactory on the BioMark HD™
and the OpenArray® platforms suggesting that care must be
taken in selecting appropriate reference genes.
Equally important as reproducibility was to achieve
consistency of gene expression measurements acrossplatforms. This would provide a possibility to directly com-
pare new measurements to previous data and to use SVM
model trained on historical microarray data for classifica-
tion of new samples measured on alternative platforms.
However, the cross-platform comparison of log2 fold
change measurement indicates modest to poor correlation
between gene expressions data measured on the different
platforms. We suggest that the major contributions to poor
correlations are attributable to either platform specific dif-
ferences in protocols, data processing or differences inher-
ent to each technology. Contributing factors may include
slight differences in probe sequences, small differences in
the location of probes or primers and the lack of industrial
standards across different technologies. Since the selection
of primers and probes in this study was based on probe
annotations, slight differences in the location of probes or
primers on the target sequence might result in the detec-
tion of different types of splice variants on the different
technologies. Previous experiments have shown that it is
possible to achieve improved correlations across platforms
using probes matched at exon levels [25]. Other groups
have also stated that differences in probes across microarray
platforms can be a major cause of discordance [26,27]. We
do not have full access to the complete primer and probe
sequences for all platforms preventing us from investigating
the actual contribution of this factor in this experiment.
We feel that the low concordance of gene expression mea-
surements between evaluated platforms and to Affymetrix®
microarray data will prevent a direct comparison of
previously generated microarray data to new measurements
on an alternative platform in this type of application.
Finally, we evaluated the overall structure and similar-
ities of gene expression measurements from the various
platforms in order to investigate if data from evaluated
platforms contained enough biological information to
distinguish sensitizers from non-sensitizers in PCA ana-
lysis. All platforms were able to distinguish strong sensi-
tizers as well as several of the moderate sensitizers from
the non-sensitizers. However, information contained in
the gene expression data were not sufficient to distinguish
weak sensitizers from non-sensitizers on any of the evalu-
ated platforms. Previous work has reported variations in
transcriptional profiles related to the relative potency of
stimulating agent [10], indicating a smaller variation be-
tween weak sensitizers and non-sensitizers in comparison
to strong and moderate sensitizers. Although significant
efforts were made in order to select target genes with
highest discriminatory power between sensitizers and
non-sensitizers in this study, the inability to accurately
classify weak sensitizers on the evaluated platforms could
potentially be an artifact generated by the smaller number
of genes included in this study (n =28) in comparison to
the complete GARD signature (n = 200). Therefore, we
filtered the Affymetrix® data set to include the same genes
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the genes selected for this study contains sufficient infor-
mation to distinguish also the weak sensitizers as the
Affymetrix® data illustrated a more obvious separation
between weak sensitizers and non-sensitizers in compari-
son to evaluated platforms (Figure 5). Considering that the
GARD signature was initially selected based on Affymetrix®
microarray data and the poor correlations observed be-
tween Affymetrix® and evaluated platforms, we suggested
that a reasonable explanation to why evaluated platforms
were not able to completely distinguish all sensitizers from
all non-sensitizers derives from differences in technology
between platforms, i.e., the same factors that contributed
to the poor correlation between platforms as discussed
above. In support of this argument, the PCA plot con-
structed from data measured on the hybridization based
nCounter® platform shows most similarities to the PCA
plot constructed from Affymetrix® data. Alternatively, the
observed differentiation between weak sensitizers and
non-sensitizers in the Affymetrix® data may also be due to
a selection bias, as the Affymetrix® data is the historical
data set used to identify the genomic predictors. There-
fore, we cannot exclude the possibility that including a
larger set of genes from the GPS to be analyzed on the
evaluated platforms might provide more information rele-
vant for the separation also of weak sensitizer as a larger
set of genes would allow for a data driven approach to
select for better predictors also on evaluated platforms. In
addition, we observed that the separation of sensitizers
were seen along the second principal component in PCA
plots for gene expression data from the BioMark HD™ and
OpenArray® data instead of along the first principal
component as seen with Affymetrix® and nCounter® data.
The observed separation along the second principal com-
ponent indicates that much of the variation in the datasets
may be attributable to systematic artifacts from the tech-
nologies and not from the transcriptional variations. This
has previously been shown for other high-throughput
technologies as reviewed by [28].
Other important parameters to consider are price per
assay, simplicity of protocols, time to results and sample
throughput. These parameters had to be balanced in
relation to the technical parameters in order to select
a suitable platform for GARD. In comparison to the
Affymetrix® platform, evaluated platforms enable higher
sample throughput, having shorter turnaround time for
results and provides more flexible solutions for focused
gene expression of a specific sets of genes. The nCounter®
platform has the additional advantage of not requiring
reverse transcription, being highly multiplexed regarding
the amount of transcripts to be measured in a single reac-
tion, requires low amount of hands-on time, provides fully
automated liquid handling steps and has the easiest work-
flow. The BioMark HD™ system is most cost effective andprovides a straightforward and simple method for data
normalization. The OpenArray® system has an easy work
flow and streamlined protocol were most liquid handling
steps are automated and enables progression from cDNA
into results in less than three hours.
In summary, all of the evaluated platforms produced
high quality gene expression data, demonstrated accept-
able reproducibility of gene expression measurements and
retained discriminatory power for separation of strong
and moderate sensitizers. Although slight differences
between the high-throughput platforms in terms of cost
per sample, sample throughput and simplicity of protocols
were observed, the evaluated platforms were superior in
relation to the microarrays when considering these para-
meters.Conclusions
In this study, we evaluated the performance of three high-
throughput platforms using a restricted set of probes from
the GARD biomarker signature. We showed that it was
possible to achieve acceptable detection sensitivity, repro-
ducibility and discriminatory power between strong and
moderate sensitizers and non-sensitizers in the GARD
assay and at the same time reduce time to results and
assay costs, simplify assay procedures and increase sample
throughput by using a high throughput platform. As a
final remark, we conclude that all of the evaluated plat-
forms are suitable candidates to replace microarrays as
the technical platform for GARD. Changing the platform
for gene expression measurement will be a first step in
order to prepare GARD for validation and industrial
screening of potential sensitizers.Methods
Chemicals
A panel of 16 chemical compounds comprising eight sen-
sitizers and eight non-sensitizers as defined by the LLNA
assay were used for stimulation of cells. The sensitizers
were 2-aminophenol, 2-nitro-1,4-phenylenediamine, 2-
hydroxyetylacrylate, p-phenylenediamine, etylenediamine,
geraniol, penicillin G and eugenol. The non-sensitizers
were propylene glycol, ethyl vanillin, 1-butanol, salicylic
acid, methyl Salicylate, dimethyl formamide and the ve-
hicle controls dimethyl sulfoxide and water. All chemicals
were purchased from Sigma-Aldrich (St. Louis, MO).
Chemical compounds were dissolved in either dimethyl
sulfoxide or water [10]. Each chemical compound was
diluted into a concentration corresponding to the GARD
input concentration. Establishment of GARD input con-
centration has been extensively described elsewhere
[10,29]. Sensitizing potency, GARD input concentration
and solvents for each chemical compound are summa-
rized in Table 2.
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Maintenance, phenotypic analysis and stimulation of the
human myeloid leukemia-derived cell line MUTZ-3 were
performed as previously described [10]. In short, pheno-
typic analysis of MUTZ-3 cells was performed using flow
cytometry prior to each experiment to ensure that cells
were not differentiated. Monoclonal antibodies used during
phenotypic analysis: CD1a (DakoCytomation, Glostrup,
Denmark), CD34, CD86, HLA-DR (BD Biosciences,
Franklin Lakes, NJ), all FITC-conjugated. CD14 (DakoCyto-
mation), CD54, CD80 (BD Biosciences), all PE-conjugated.
Propidium iodide (BD Biosciences) was used to estimate
cell viability and FITC- and PE- conjugated mouse IgG1
(BD Biosciences) were used as isotype controls. Samples
were analyzed on FACSCanto II instrument using FACS
Diva software for data acquisition. A total of 10, 000 events
were acquired and data were imported into FCS Express
V4 (De Novo Software, Los Angeles, CA) for further
analysis. Gates were set to exclude non-viable cells and cell
debris based on light scattering properties. During chemical
stimulation, MUTZ-3 cells were seeded in 24 well-plates
and stimulated with chemical compounds. All stimulations
were performed in biological triplicates, performed at
different time points using different cell cultures. After 24 h
incubation, cells were harvested. Maturity state of the cells
were controlled by analyzing cell surface expression of
CD86 using flow cytometry as described above. In parallel,
harvested cells were lysed in TRIzol® reagent (Life
Technologies™, Carlsbad, CA) and stored at −20°C until
RNA extraction.
RNA extraction and cDNA preparation
RNA was isolated from chemically stimulated MUTZ-3
cells using TRIzol® reagent. Purity and concentration
of RNA in each sample were confirmed using Agilent
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA)
according to standard protocol provided by the manufac-
turer. Each sample was diluted into 200 ng/μl of total RNA
and divided into two identical 10 μl samples (2 μg total
RNA). One of the samples was further diluted into 20 ng/μl
of total RNA and analyzed on nCounter® platform. The
other sample was reverse transcribed into cDNA using
the High capacity cDNA reverse transcription kit (Life
Technologies™) according to standard protocols provided
by the manufacturer. In short, 10 μl of a reverse transcrip-
tion master mix containing MultiScribe™ reverse transcript-
ase and random primers was prepared for each sample and
added to 2 μg of total RNA (10 μl at 200 ng/μl) for a 20 μl
reaction. The following thermal protocol was used: 25°C,
10 min; 37°C, 120 min; 85°C, 5 min; 4°C hold. A reaction
efficiency of 100% was assumed. The cDNA samples were
divided into two identical 10 μl samples and stored at
−20°C until further downstream processing for analysis on
the BioMark HD™ platform and the OpenArray® platform.Primers and probes
A total of 33 transcripts were selected for the evaluation.
The set of transcripts included 30 genes from GPS as
well as three reference genes (ABCB4, HPRT1, GAPDH)
for normalization of data. A probe set targeting the 33
transcripts was obtained from NanoString® (NanoString®
Technologies, Seattle, WA) for analysis on the nCounter®
platform. Pairs of primers targeting the same 33 transcripts
were obtained from DELTAGene™ (Fluidigm®, San Francisco,
CA) for analysis on the BioMark HD™ platform. DELTA-
Gene™ quantification of gene expression was based on
SYBR® Green hybridization chemistry. Pairs of primers and
probes targeting the same 33 transcripts were obtained
from Life Technologies™ (Life Technologies™, Carlsbad,
CA) for analysis on the OpenArray® platform. OpenArray®
quantification of gene expression was based on TaqMan®
hydrolysis chemistry. A complete list of accession numbers
for transcripts is provided in Table 3.
Measurement of gene expression on nCounter® system
Total RNA samples from chemically stimulated MUTZ-3
cells, prepared as described above, were sent to NCCR
Frontiers in Genetics (Geneva, Switzerland) on dry ice for
analysis on the nCounter® system. An amount of 200 ng
(10 μl) of total RNA from each sample was analyzed on the
nCounter® system using standardized protocol for gene
expression analysis provided by NanoString®. Each sample
was analyzed in a separate multiplexed reaction. Data was
imported into nSolver™ analysis software using NanoString®
raw code count collector tool. Normalization of data was
performed according to NanoString® analysis guidelines. For
negative control normalization, the mean of the counts for
all negative controls in each sample plus two standard devia-
tions was subtracted from counts for the remaining tran-
scripts in same sample. For positive control normalization, a
normalization reference was first generated by calculating
the sum of the counts for the positive spike in transcripts
in each sample and then calculating the average of these
sums across all samples. A scaling factor for each sample
was then calculated by dividing the sum of the counts from
the positive spike in transcripts from each sample with the
normalization reference. Remaining code counts were
multiplied by the sample specific scaling factor. Normalized
counts were compiled into Microsoft Excel and further
normalized against the reference genes GAPDH and
HPRT1. For normalization to reference genes, the geo-
metric mean of the counts for GAPDH and HPRT1 for
each sample was calculated, and the average across all
samples was used as the normalization reference. A scaling
factor for normalization of remaining code counts was cal-
culated and applied as described above for positive control
normalization. Reference genes were selected based on
internal control parameters included in an nSolver Excel
macro developed by NCCR Frontiers in Genetics using the
Forreryd et al. BMC Genomics 2014, 15:379 Page 15 of 17
http://www.biomedcentral.com/1471-2164/15/379geNorm method [30]. For a gene to be considered as
detected, the normalized gene counts for a specific tran-
script had to be significantly (Student’s t test, p < 0.05) above
background threshold count value for the negative controls.
Measurement of gene expression on BioMark™ HD system
Specific Target Amplification (STA) was performed on
cDNA samples using TaqMan® PreAmp Master Mix
(Life Technologies™) and standard protocols provided by
manufacturer. In short, 1.25 μl of each cDNA sample was
combined with 2.5 μl of 2x TaqMan PreAmp Master
Mix in wells of a 96-well PCR plate. 0.5 μl of a pre-
amplification primer mix comprising a mixture of pooled
DELTAGene™ assays (500nM of each primer) was mixed
with 0.75 μl dH2O and added to each sample. The PCR
plate was transferred to a thermal cycler and subjected to
the following thermal protocol: 95°C, 10 min; 14 cycles
(95°C ,15 s; 60°C, 4 min); 4°C hold. Samples were treated
with Exonuclease I (New England BioLabs, Ipswich, MA) to
remove unincorporated primers by adding 2 μl (at 4 U/μl)
to each STA reaction. The PCR plate was once again trans-
ferred to a thermal cycler and subjected to the following
thermal protocol: 37°C, 30 min; 80°C, 15 min; 4°C hold. All
samples were then diluted 10× in TE-buffer (10 mM Tris–
HCl, 0.1 mM EDTA, pH 8) (Sigma-Aldrich) and sent to
Veterinærinstituttet (DTU, Copenhagen, Denmark) on dry
ice for analysis on the BioMark HD™ system. Operation of
instruments and handling and processing of the IFC
controller HX were performed using standardized protocol
for gene expression analysis provided by Fluidigm®. Samples
were prepared for loading on a 96:96 Dynamic array™ IFC
by combining 2.25 μl of each preamplified cDNA sample
with 2.5 μl 2× SsoFast™ EvaGreen® Supermix with low ROX
(BioRad, Hercules, CA) and 0.25 μl 20× DNA binding dye
loading reagent (Fluidigm®). A total of 5 μl of each pre amp-
lified cDNA sample and 5 μl of each DeltaGene assay were
dispensed into their corresponding inlets on the Dynamic
array™ and samples were subjected to RT-qPCR reaction
using the following thermal cycling protocol: 70°C, 40 min;
60°C, 30 s; 95°C, 1 min; 35 cycles (96°C, 5 s; 60°C, 20 s) and
melting curve using a ramp from 60°C to 95°C at 1°C/3 s.
Data was collected with Fluidigm® Real-Time PCR analysis
software using linear baseline correction method and global
auto Cq threshold method. Normalizations of data were per-
formed using comparative Cq method [31]. The reference
gene used in this study, GAPDH, was selected based on in-
ternal control parameters included in software. A transcript
was considered as undetected in a certain chemical stimula-
tion when unprocessed Cq value exceeded 35.
Measurement of gene expression on OpenArray® system
cDNA samples from chemically stimulated MUTZ-3 cells,
prepared as described above, were sent to Life Technologies™
demo laboratory (Saint Aubin, France) on dry ice for analysison the OpenArray® system. Loading of samples, operation
of instruments and RT-qPCR cycling were performed using
standardized protocol for gene expression analysis provided
by Life Technologies™. In short, 1.2 μl of each cDNA
sample was combined with 2.5 μl of 2× TaqMan® Open-
Array® Real-Time PCR Master Mix (Life Technologies™)
and 1.3 μl dH2O and transferred to an OpenArray® 384-
Well Sample Plate. Samples were loaded into the custom
designed OpenArray® plates using QuantStudio™ 12 K flex
AccuFill™ system. The OpenArray® plates were removed
from the AccuFill™ system, transferred to an OpenArray®
carrier, covered with immersion fluid (All reagents from
QuantStudio™ 12 K flex OpenArray® accessories kit, Life
Technologies™) and loaded into the QuantStudio™ 12 K flex
instrument for RT-qPCR cycling. Samples were subjected
to standard thermal cycling protocol provided by Life
technologies™. Data was collected with Life Technologies™
Expression Suit analysis software v 1.0.3 using linear
baseline correction method and the global auto Cq thresh-
old method. Normalization of data was performed using
the comparative Cq method [31]. The reference gene used
in this study, GAPDH was selected based on internal
control parameters included in software. A transcript was
considered as undetected in a certain chemical stimulation
when unprocessed Cq value exceeded 35.
Measurement of gene expression on Affymetrix® HuGene
1.0 ST arrays
Affymetrix® gene expression data used for comparative
analyses in this study was obtained from previously pub-
lished experiments [10]. Maintenance, phenotypic analysis
and stimulation of cells were carried out as described
above. Preparation of cDNA, hybridization, washing and
scanning of Human Gene 1.0 ST Arrays (Affymetrix®, Santa
Clara, CA) as well as RMA normalization of data was
performed according to standardized protocol provided by
the manufacturer (Affymetrix®) and as previously described
[10]. Gene expression data was filtered to contain only the
30 genes from the 16 chemical compound stimulations as
analyzed by nCounter®, BioMark HD™ and OpenArray®.
Inter-platform consistency
Inter-platform consistency was measured by pair-wise
plotting of averaged log2 fold change data of gene ex-
pression measurements obtained on the various
platforms. Results were evaluated by calculating Pearson
correlation coefficient and linear fits to the log2 fold
change ratios. Expression ratios were calculated as
follows:
Log2FCAffymetrixW ¼ μsample‐μcontrol
Log2FCnCounterW ¼ Log2 μsample=μcontrol
 
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 
Where μsample is the normalized mean for chemically
stimulated samples and μcontrol is the normalized mean
for vehicle controls. For PCR-based methods, ΔCqsample
is the normalized mean quantification cycle for chem-
ically stimulated samples and ΔCqcontrol is the normal-
ized mean quantification cycle for vehicle control.
Calculations accounts for the fact that Cq values ob-
tained from the RT-qPCR methods as well as the RMA
normalized Affymetrix® data were already in log-space.
Comparison of transcriptional profiles
Normalized gene expression measurements from each
platform were compiled into the software Qlucore
Omics Explorer 2.1 (Qlucore AB, Lund, Sweden). Gene
expression data was filtered to include only those genes
detected in at least two of the three replicates. Data was
investigated and visualized using Principal Component
Analysis.
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